Ⓐ
PeptiBrief
Endogenous gastrointestinal peptide

Xenin

An endogenous gastrointestinal peptide involved in motility, gastric emptying and incretin-linked metabolic signalling.

Evidence confidence

Human
3/5
Multiple human studies
2 citations
Animal
Not yet assessed
Trust Engine review pending.
Mechanistic
Not yet assessed
Trust Engine review pending — see editorial links below.
Editorial evidence links exist, but this category has not yet completed Trust Engine assessment.
Safety
Not yet assessed
Trust Engine review pending.

Claimed uses

Mechanisms

Safety notes

Exogenous xenin can cause nausea, abdominal symptoms, diarrhoea and altered gastric emptying. Long-term safety is unknown.

Regulation
  • No approved xenin medicine for obesity, diabetes or gastrointestinal disease.

References

  1. Xenin-25 delays gastric emptying and reduces postprandial glucose levels in humans · 2014
  2. Xenin-25 amplifies GIP-mediated insulin secretion in humans with normal and impaired glucose tolerance but not type 2 diabetes · 2012
Last reviewed
12 July 2026
Important PeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.